Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis
CONCLUSIONS: CT(A) and CT showed improved ORR compared with alternative regimens. CT(A) combined with PD-1/PD-L1 or PARP inhibitors significantly increased PCR rates. Comprehensive assessment of both ORR and safety indicated that CT(A) represents an optimal neoadjuvant therapy for HR+/HER2- breast cancer, whereas AI + CDK4/6 inhibitors rank solely behind chemotherapy.REGISTRATION: International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) registration number INPLASY202440092.PMID:38693054 | DOI:10.1080/14737140.2024.2350105
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Authors: Ruiliang Chen Yushuai Yu Jie Zhang Chuangui Song Chuan Wang Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | HER2 | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Toxicology